Northwest Biotherapeutics Inc
Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain can… Read more
Northwest Biotherapeutics Inc (NWBO) - Total Liabilities
Latest total liabilities as of September 2025: $139.26 Million USD
Based on the latest financial reports, Northwest Biotherapeutics Inc (NWBO) has total liabilities worth $139.26 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Northwest Biotherapeutics Inc - Total Liabilities Trend (2000–2024)
This chart illustrates how Northwest Biotherapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Northwest Biotherapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Northwest Biotherapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ananti Inc
KQ:025980
|
Korea | ₩849.06 Billion |
|
Cembre S.p.A.
F:J0L
|
Germany | €72.67 Million |
|
Yuilrobotics Co. Ltd.
KQ:388720
|
Korea | ₩19.59 Billion |
|
Diversified Royalty Corp
PINK:BEVFF
|
USA | $326.97 Million |
|
Kura Sushi USA Inc
NASDAQ:KRUS
|
USA | $214.31 Million |
|
Hidili Industry International Development Limited
PINK:HIIDQ
|
USA | $10.78 Billion |
|
Alight Inc
NYSE:ALIT
|
USA | $3.53 Billion |
|
Garware Hi-Tech Films Limited
NSE:GRWRHITECH
|
India | ₹3.25 Billion |
Liability Composition Analysis (2000–2024)
This chart breaks down Northwest Biotherapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Northwest Biotherapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Northwest Biotherapeutics Inc (2000–2024)
The table below shows the annual total liabilities of Northwest Biotherapeutics Inc from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $121.22 Million | +29.45% |
| 2023-12-31 | $93.64 Million | -41.27% |
| 2022-12-31 | $159.43 Million | -2.88% |
| 2021-12-31 | $164.15 Million | -58.53% |
| 2020-12-31 | $395.85 Million | +651.19% |
| 2019-12-31 | $52.70 Million | -26.63% |
| 2018-12-31 | $71.83 Million | -25.34% |
| 2017-12-31 | $96.20 Million | +21.15% |
| 2016-12-31 | $79.41 Million | +5.21% |
| 2015-12-31 | $75.47 Million | -19.25% |
| 2014-12-31 | $93.47 Million | +374.72% |
| 2013-12-31 | $19.69 Million | +55.94% |
| 2012-12-31 | $12.63 Million | -75.90% |
| 2011-12-31 | $52.38 Million | +87.24% |
| 2010-12-31 | $27.98 Million | +34.58% |
| 2009-12-31 | $20.79 Million | +50.86% |
| 2008-12-31 | $13.78 Million | +375.34% |
| 2007-12-31 | $2.90 Million | -55.08% |
| 2006-12-31 | $6.45 Million | -46.44% |
| 2005-12-31 | $12.05 Million | +108.64% |
| 2004-12-31 | $5.78 Million | +575.44% |
| 2003-12-31 | $855.00K | -68.29% |
| 2002-12-31 | $2.70 Million | +6.10% |
| 2001-12-31 | $2.54 Million | -59.06% |
| 2000-12-31 | $6.21 Million | -- |